ArticleLeukemia2003
Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia.
Article in Leukemia, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis.PloS one · 2014Pooled it
- The Intersection of Lynch Syndrome and Hematological Malignancies: A Rare Short Report.EJHaem · 2025Article
- Improving targeted small molecule drugs to overcome chemotherapy resistance.Cancer reports (Hoboken, N.J.) · 2024Review
- DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.International journal of molecular sciences · 2022Review
- Epigenetic Drugs and Their Immune Modulating Potential in Cancers.Biomedicines · 2022Review
- Precision medicine in the treatment stratification of AML patients: challenges and progress.Oncotarget · 2018Review
- National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Article
- Epigenetic regulation of DNA repair machinery in Helicobacter pylori-induced gastric carcinogenesis.World journal of gastroenterology · 2015Review
- Novel agents for the treatment of childhood acute leukemia.Therapeutic advances in hematology · 2015Review
- DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.Chromosoma · 2014Review
- Therapy-related myelodysplasia and acute myeloid leukemia.Seminars in oncology · 2013Article
- DNA methyltransferases, DNA damage repair, and cancer.Advances in experimental medicine and biology · 2013Review
- Subsequent malignant neoplasms after hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012Review
- Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Review
- Epigenetic changes of DNA repair genes in cancer.Journal of molecular cell biology · 2011Review
- Novel targeted drug therapies for the treatment of childhood acute leukemia.Expert review of hematology · 2009Article
- Epigenetics in acute myeloid leukemia.Seminars in oncology · 2008Review
- Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.Paediatric drugs · 2008Review
- Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients.Leukemia · 2005Article
- Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.International journal of hematology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hMLH1 and hMSH2 genes are involved in the DNA mismatch repair (MMR) pathway. Defects in either of these genes have been associated with genetic instability in a wide variety of malignancies. A molecular mechanism involved in aberrant MMR gene expression is the epigenetic silencing of transcription by promoter methylation. The importance of MMR promoter methylation in leukemia is presently unclear and we have therefore undertaken a detailed analysis of the promoter regions of hMLH1 and hMSH2 using the technique of bisulfite genomic sequencing. DNA from 55 patients with acute myeloid leukemia (AML) including 23 patients with therapy-related AML (t-AML) have been analyzed. Two patients with de novo AML demonstrated extensive methylation throughout the whole hMLH1 region sequenced, one of whom had previously shown widespread genetic instability, measured as microsatellite instability (MSI). However methylation of hMLH1 was not found in t-AML which has previously been associated with MSI. In addition, methylation was seen at a restricted region of the hMLH1 promoter in both AML patients and healthy controls. The significance of this methylated region of the hMLH1 promoter is uncertain, however, our results confirm that in some patients with AML extensive methylation of hMLH1, but not of hMSH2 may occur, and as is the case in solid tumors this can be associated with the presence of a defective DNA mismatch repair pathway resulting in MSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.